Researchers in China recently published a study in Science Translational Medicine describing a new antibody cocktail for protection against two common viruses. The proposed preventative treatment consists of antibodies identified in pediatricians who have been repeatedly exposed to viruses throughout their careers, causing them to build up an immune system capable of defending against an array of pathogens.
The respiratory syncytial virus (RSV) causes mild cold-like symptoms in healthy adults, but is the leading cause of lower respiratory tract infections in children, accounting for 30–50% of hospitalizations. The human metapneumovirus (hMPV) is the second most common cause of lower respiratory tract infections in children, accounting for 6–15% of hospitalizations. Both are also major causes of severe respiratory infections in older adults and immunocompromised people.
While RSV vaccines exist, they are currently only approved for older adults, as pediatric vaccines have faced safety challenges associated with enhanced respiratory disease risks. Vaccination before immune-ablative therapies in immunocompromised individuals has also been shown to be ineffective. Meanwhile, there are currently no approved therapies or prophylactics for hMPV.








